Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338
This study is recruiting at 19 US sites in 14 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumors
- Metastatic Solid Tumors
- Non-small Cell Lung Cancer (NSCLC)
- NSCLC
- Colorectal Cancer (CRC)
- CRC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Revolution Medicines, Inc.
- Last updated on ClinicalTrials.gov
- November 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Honor Health Research Institute · Scottsdale, AZ
California · 2
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, CA
Connecticut · 1
- Eastern Connecticut Hematology and Oncology Associates · Norwich, CT
Kentucky · 1
- University of Kentucky HealthCare (UK HealthCare) · Lexington, KY
Minnesota · 1
- Health Partners Cancer Center at Regions Hospital · Saint Paul, MN
Missouri · 1
- Siteman Cancer Center · St Louis, MO
New Jersey · 1
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, NJ
New York · 2
- Icahn School of Medicine at Mount Sinai · New York, NY
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC · New York, NY
Ohio · 2
- University Hospitals Cleveland Medical Center · Cleveland, OH
- The Jame Outpatient Care West Campus · Columbus, OH
Oregon · 1
- OHSU Knight Cancer Institute · Portland, OR
Pennsylvania · 1
- UPMC Hillman Cancer Center · Pittsburgh, PA
Tennessee · 1
- Tennessee Oncology · Nashville, TN
Texas · 3
- MD Anderson Cancer Center · Houston, TX
- NEXT Dallas · Irving, TX
- NEXT Oncology · San Antonio, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.